Professor of Medicine, University Tex Houston
Oncology
Dr. Frank V. Fossella, MD
|
|
Give Review
Dr. Frank V. Fossella practices Oncology. He went to medical school at Baylor College of Medicine. He received 4 awards: "America's Top Doctors", "Top Doctors:SE Texas", "America's Top Doctors for Cancer" and "Super Doctor". Frank Fossella is a published doctor. He has 31 publications published. The most current publication "Longitudinal associations between caregiver burden and patient and spouse distress in couples coping with lung cancer." He accepts Medicare payments and is listed with Medicare.gov.
Publications
- Prognostic Value of Positron Emission Tomography/Computed Tomography Findings in Limited-stage Small Cell Lung Cancer Before Chemoradiation Therapy.
- Longitudinal associations between caregiver burden and patient and spouse distress in couples coping with lung Cancer.
- Phase II Trials of Imatinib Mesylate and Docetaxel in Patients with Metastatic Non-small Cell Lung Cancer and Head and Neck Squamous Cell Carcinoma.
- Positron Emission Tomography/Computed Tomography-Guided Intensity-Modulated Radiotherapy for Limited-Stage Small-Cell Lung Cancer.
- Weekly alternating therapy with irinotecan plus cisplatin and etoposide plus cisplatin in the treatment of patients with extensive small Cell lung carcinoma.
- Phase 2 study of carboplatin, docetaxel, and bevacizumab as frontline treatment for advanced nonsmall-cell lung Cancer.
- Phase II study of vinorelbine and docetaxel in the treatment of advanced non-small-cell lung Cancer as frontline and second-line therapy.
- Dose escalation of gemcitabine is possible with concurrent chest three-dimensional rather than two-dimensional radiotherapy: a phase I trial in patients with stage III...
- Many patients 80 years and older with advanced non-small cell lung Cancer (NSCLC) can tolerate chemotherapy.
- Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung Cancer.
- Asian ethnicity as a predictor of response in patients with non-small-cell lung Cancer treated with gefitinib on an expanded access program.
- Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung Cancer.
- Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung Cancer.
- Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane-refractory/resistant nonsmall Cell lung carcinoma.
- High mutagen sensitivity in peripheral blood lymphocytes predicts poor overall and disease-specific survival in patients with stage III non-small cell lung Cancer trea...
- Mutagen sensitivity may predict lung protection by amifostine for patients with locally advanced non-small cell lung Cancer treated by chemoradiotherapy.
- Pemetrexed in advanced NSCLC: a review of the clinical data.
- Phase I study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in solid Tumors.
- Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung Cancer: report of a randomized comparative trial.
- Targeted molecules in small cell lung Cancer.
- Pemetrexed for treatment of advanced non-small cell lung Cancer.
- Equivalent outcome of patients with clinical Stage IIIA non-small-cell lung Cancer treated with concurrent chemoradiation compared with induction chemotherapy followed...
- Phase I study of weekly alternating therapy with irinotecan/cisplatin and etoposide/cisplatin for patients with small-cell lung Cancer.
- Dose-dense therapy with a novel irinotecan regimen for small-cell lung Cancer.
- A phase I study of topotecan/paclitaxel alternating with etoposide/cisplatin and thoracic irradiation in patients with limited small cell lung Cancer.
- Safety and pharmacokinetic effects of TNP-470, an angiogenesis inhibitor, combined with paclitaxel in patients with solid Tumors: evidence for activity in non-small-ce...
- The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall Cell lung carcinoma: potential for decreased toxicity an...
- Docetaxel for previously treated non-small-cell lung Cancer.
- Docetaxel in second-line treatment of non-small-cell lung Cancer.
- Phase I trials of pemetrexed.
Schools
Baylor Coll Of Med
Baylor College Of Med
Procedures Preformed
- Cardiac MRI (Magnetic Resonance Imaging) of Heart or Chest
- Thoracentesis
Conditions Treated
- Adrenal Gland Cancer
- Anemia
- Basal Cell Carcinoma
- Bladder Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
- Choice Plus POS II
- Amerigroup (Wellpoint)
- Blue Card PPO
- Blue Choice
- CHAMPVA
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- LocalPlus
- Open Access Plus
- Commercial Insurance Company
- CoreSource
- First Health (Coventry Health Care) PPO
- Choice Care PPO
- Medical Mutual of Ohio
- Medicare MCR
- MultiPlan PPO
- PHCS Network PPO
- National Elevator
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- United Healthcare
Awards
- America's Top Doctors
- Top Doctors:SE Texas
- America's Top Doctors for Cancer
- Super Doctor
Education
-
Baylor College of Medicine
Hospital
-
University of Texas M.D. Anderson Cancer Center
Drug Facts
| NPI NUMBER | 1003991035 | |
| NPPES Provider LastName | FOSSELLA | |
| NPPES Provider FirstName | FRANK | |
| NPPES Provider ZIPCode | 770304009 | |
| NPPES Provider State | TX | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 1038.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 111.0 | |
| Percent Opioid Claims | 10.69 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1003991035 |
| Last Name Of The Provider | FOSSELLA |
| First Name Of The Provider | FRANK |
| View All |
Similar Doctors
|
|
Dr. Marc S. Hoffmann, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Emil J. Freireich, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Shamail Butt, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Shagufta N. Naqvi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John C. Araujo, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ralph G. Zinner, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. James L. Abbruzzese, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
Dr. Khaled W. Jabboury, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Martin N. Raber, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Yesid Alvarado Valero, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Stacy L. Moulder, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Eric H. Bernicker, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Uzma Iqbal, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Faye M. Johnson, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
Dr. Philip A. Salem, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Maria A. Scouros, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Tejal A. Patel, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ellen E. Manzullo, MD
This Doctor is OpenDoctor Recommended.
|